Sequent Scientific Ltd Share Price Today Live NSE/BSE

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Sequent Scien.

Master Rating:
Sequent Scientific has an operating revenue of Rs. 1,391.10 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 10% is healthy, ROE of 13% is good. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 2 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 146 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Sequent Scientific Ltd Forecast

Price Estimates

2,000(9.8%)

1,758(-3.5%)

1,590(-12.7%)

Ratings

Eps And Sales Estimates

Sales(Cr) EPS

Sequent Scientific Ltd Synopsis

NSE-Medical-Diversified

Sequent Scientific is involved in the business activities of Manufacture of veterinary preparations. Company’s Total Operating Revenue is Rs. 265.46 Cr. and Equity Capital is Rs. 49.67 Cr. for the Year ended 31/03/2021. Sequent Scientific Ltd. is a Public Limited Listed company incorporated on 28/06/1985 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1985PLC036685 and registration number is 036685.

Market Cap

INR 3,800.08 Cr
Sales

INR 236.81 Cr
Shares in Float

11.43 Cr
No of Funds

61 K

Yield

0.33%
Book Value

3.69
U/D Vol Ratio

0.7

LTDebt/Equity

2%
Alpha

-0.13
Beta

1.22

Sequent Scientific Ltd Ownership

Owner Name	Jun-21	Mar-21	Dec-20
Promoters	53.86%	53.86%	53.86%
Mutual Funds	2.1%	2.68%	4.51%
Foreign Portfolio Investors	13.6%	13.15%	10.2%
Financial Institutions/ Banks	0%	0%	0%
Individual Investors	19.04%	19.28%	18.47%
Others	11.4%	11.03%	12.96%

Sequent Scientific Ltd Management

Name	Designation
Dr. Kamal K Sharma	Chairman & Ind.Director
Mr. Manish Gupta	Managing Director & CEO
Mr. Sharat Narasapur	Joint Managing Director
Mr. Gregory John Andrews	Non Executive Director
Mr. Neeraj Bharadwaj	Non Executive Director
Dr. Fabian Kausche	Non Executive Director
Mr. Rahul Mukim	Non Executive Director
Mr. Milind Sarwate	Independent Director
Dr.(Mrs.) Kausalya Santhanam	Independent Director

Sequent Scientific Ltd Financials

Standalone Consolidated

Quarterly P&L
Annual P&L
Cash Flow
Balance Sheet
Ratios

INDICATOR	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020
Oper Rev Qtr Cr	50.105	46.657	69.479	70.572	69.641
Operating Expenses Qtr Cr	54.687	50.818	66.6003	57.335	59.171
Operating Profit Qtr Cr	-4.582	-4.161	2.8787	13.237	10.47
Depreciation Qtr Cr	2.54	2.308	2.607	2.193	2.164
Interest Qtr Cr	0.279	0.167	0.25	0.602	0.727
Tax Qtr Cr	-1.2772	-0.2638	1.3869	3.942	1.818
Net Profit Qtr Cr	4.2872	-0.6092	4.6428	12.169	9.214

INDICATOR	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Total Revenue Annual Cr	285.423	241.894	180.216	130.276	109.782
Operating Expenses Annual Cr	230.167	205.096	163.572	124.393	121.273
Operating Profit Annual in Cr	35.29	22.237	2.688	-18.386	-30.558
Depreciation Cr	9.128	8.95	7.221	3.667	3.252
Interest Annual Cr	2.68	5.035	3.22	0.392	0.423
Tax Annual Cr	8.774	1.472	-1.383	2.867	0
Net Profit Annual Cr	32.113	21.341	7.586	406.407	-0.012

INDICATOR	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Cash from Operating Activity Annual Cr	2.338	30.204	73.798	-4.339	-24.043
Cash from Investing Activity Annual Cr	170.001	-10.385	-114.064	15.925	-46.843
Cash from Financing Annual Activity Cr	-174.777	-18.012	40.336	-11.776	70.971
Net Cash Flow Annual Cr	-2.438	1.807	0.07	-0.19	0.085

INDICATOR	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Total ShareHolders Funds Annual Cr	1029.511	886.217	917.791	948.617	1257.33
Fixed Assets Annual Cr	70.121	73.129	52.457	26.804	220.114
Total Non Current Assets Annual Cr	983.557	885.698	932.448	836.93	1081.876
Total Current Assets Annual Cr	118.565	111.672	86.445	140.544	368.46
Total Assets Annual Cr	1102.122	997.37	1018.893	977.474	1450.336

INDICATOR	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Book Value Per Share Annual Rs	41.4506	35.6812	37.177	38.92	51.5858
ROE Annual %	3.11	2.4	0.82	42.84	0
ROCE Annual %	4.47	3.07	1	0.23	-1.15
Total Debt to Total Equity Annual	-	-	-	-	-
EBDIT Annual Margin %	20.81	16.18	10.01	5.54	-12.66

Quarterly P&L
Annual P&L
Cash Flow
Balance Sheet
Ratios

INDICATOR	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020
Oper Rev Qtr Cr	350.551	320.509	361.8247	358.214	346.272
Operating Expenses Qtr Cr	330.873	300.353	318.5431	291.909	289.88
Operating Profit Qtr Cr	19.678	20.156	43.2816	66.305	56.392
Depreciation Qtr Cr	13.207	12.574	12.683	11.585	13.303
Interest Qtr Cr	3.263	3.023	3.177	6.2	7.361
Tax Qtr Cr	-9.875	4.581	5.4847	11.639	7.96
Net Profit Qtr Cr	14.3	0.873	20.6329	37.227	21.261

INDICATOR	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Total Revenue Annual Cr	1369.978	1189.333	1047.979	864.419	694.646
Operating Expenses Annual Cr	1149.545	1008.922	914.373	764.858	640.624
Operating Profit Annual in Cr	212.07	170.322	124.934	82.98	42.945
Depreciation Cr	50.598	50.622	41.92	41.343	40.073
Interest Annual Cr	24.383	35.714	32.802	33.069	28.34
Tax Annual Cr	32.177	12.029	2.007	13.457	-0.527
Net Profit Annual Cr	95.442	69.905	48.66	421.566	-13.824

INDICATOR	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Cash from Operating Activity Annual Cr	114.754	115.33	116.024	45.239	-7.19
Cash from Investing Activity Annual Cr	9.648	-72.27	-67.695	7.168	-116.178
Cash from Financing Annual Activity Cr	-138.754	-42.753	-20.084	-56.959	147.438
Net Cash Flow Annual Cr	-14.352	0.307	28.245	-4.552	24.07

INDICATOR	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Total ShareHolders Funds Annual Cr	727.651	742.76	706.692	647.577	976.791
Fixed Assets Annual Cr	392.247	407.676	299.784	291.817	492.639
Total Non Current Assets Annual Cr	678.974	814.165	787.89	804.747	1176.877
Total Current Assets Annual Cr	713.585	704.137	599.987	538.015	727.737
Total Assets Annual Cr	1392.559	1518.302	1387.877	1342.762	1904.614

INDICATOR	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Book Value Per Share Annual Rs	31.2564	31.7066	30.2564	28.0862	40.7822
ROE Annual %	13.11	9.41	6.88	65.09	-1.41
ROCE Annual %	18.22	12.37	9.6	6.38	1.12
Total Debt to Total Equity Annual	-	-	-	-	-
EBDIT Annual Margin %	16.18	15.29	12.85	11.74	7.9

Sequent Scientific Ltd Technicals

EMA & SMA

CURRENT PRICE

153 (0.07)

- Bullish Moving Averages 1
- Bearish Moving Averages 15

EMA

EMA SMA

20 Day

170.88
50 Day

191.4
100 Day

212.73
200 Day

243.67

Sequent Scientific Ltd Resistance and support

152.79 PIVOT

First Resistance

155.07
Second Resistance

157.24
Third Resistance

159.52

First Support

150.62
Second Support

148.34
Third Support

146.17

RSI

30.76
MFI

30.34

MACD

-12.01
MACD signal line

-10.36

Sequent Scientific Ltd Delivery and Volume

Period	NSE + BSE Volume Avg	NSE + BSE Delivery Volume Avg	NSE + BSE Delivery Volume %
Day	1,481,900	55,363,784	37.36%
Week	1,698,119	68,094,556	40.1%
1 Month	1,390,290	63,897,712	45.96%
6 Month	1,772,350	61,855,004	34.9%

Sequent Scientific Ltd Price change analysis

-22.6

Over 1 month

Low High

144.75 194.9

-78.85

Over 3 month

Low High

144.75 239.7

-111.7

Over 6 months

Low High

144.75 336.5

-8.85

Over Year

Low High

144.75 336.5

Similar Stocks

Company Name	52 Week ()	Market Price ()	Volume
Solara Active Pharma Sciences Ltd	1,859.30	1,183.40 (-0.96%)	3805
Novartis India Ltd	1,099.00	778.00 (0.30%)	1645
J B Chemicals & Pharmaceuticals Ltd	1,984.75	1,593.00 (-0.27%)	2997
Ajanta Pharma Ltd	2,420.00	2,125.00 (2.25%)	2917

News

SEQUENT SCIENTIFIC LTD. - 512529 - Compliance Under Regulati

In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Read More

Sequent Scientific Ltd - 512529 - Intimation Under Regulatio

With reference to the captioned subject, we would like to inform you that upon voluntary application made by Elysian Life Science Private Li Read More

Sequent Scientific Ltd - 512529 - Announcement under Regulat

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Read More

Sequent Scientific Ltd - 512529 - Announcement under Regulat

Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Read More

Q2FY22 Result Quarterly Announced for Sequent Scientific Ltd

Financial Highlights: Revenues at Rs. 3,506 Million PAT after minority interest at Rs. 143 Million PAT margin at 4.1% Commenting on the Co Read More

Blogs